Investors braced for a bumpy ride ahead of United Therapeutics'
What analysts say:
- Buy, sell, or hold?: The majority of analysts back United Therapeutics as a buy. But with 71.4% of analysts rating it a buy, United Therapeutics is still below the mean analyst rating of its nearest 10 competitors, which average 72.1% buys. Analysts don't like United Therapeutics as much as competitor Teva Pharmaceutical overall. Twenty-four out of 32 analysts rate Teva Pharmaceutical a buy compared to 10 out of 14 for United Therapeutics. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $205.1 million in revenue this quarter. That would represent a rise of 23.2% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.87 per share. Estimates range from $0.44 to $1.28.
What our community says:
CAPS All-Stars are solidly behind the stock, with 93.3% giving it an outperform rating. The greater community backs the All-Stars, as 91.8% give it a rating of outperform. Fools have embraced United Therapeutics, though the message boards have been quiet lately with only 62 posts in the past 30 days. Despite the majority sentiment in favor of United Therapeutics, the stock has a middling CAPS rating of three out of five stars.
United Therapeutics' income has fallen year over year by an average of 47.9% over the past five quarters.
For all our United Therapeutics-specific analysis, including earnings and beyond, add United Therapeutics to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.